Linezolid + Vancomycin

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Methicillin-Resistant Staphylococcus Aureus (MRSA)

Conditions

Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia

Trial Timeline

Nov 1, 2008 → Jun 1, 2013

NCT ID

NCT01561469

About Linezolid + Vancomycin

Linezolid + Vancomycin is a pre-clinical stage product being developed by Pfizer for Methicillin-Resistant Staphylococcus Aureus (MRSA). The current trial status is completed. This product is registered under clinical trial identifier NCT01561469. Target conditions include Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01561469	Pre-clinical	Completed	Nov 1, 2008	Jun 1, 2013	Methicillin-Resistant Staphylococcus Aureus (MRSA)
NCT00087490	Approved	Completed	Oct 1, 2004	Jul 1, 2007	Skin/Soft Tissue Infections
NCT00035425	Phase 3	Completed	Nov 1, 2001	Nov 1, 2002	Febrile Neutropenia

Competing Products

2 competing products in Methicillin-Resistant Staphylococcus Aureus (MRSA)

See all competitors

Product	Company	Stage	Hype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin	AbbVie	Phase 3	77
Imipenem/cilastatin	Pfizer	Approved	84

Other Products from Pfizer